Synovial sarcoma X breakpoint protein 4 (SSX4)

Synovial sarcoma X breakpoint protein 4 (SSX4) is a member of the SSX protein family of cancer-testis antigens, encoded on the X chromosome and characterized by highly restricted expression in normal tissues (primarily testicular germ cells) but frequent aberrant expression in a variety of cancers. SSX4 acts as a transcriptional corepressor, likely by interacting with chromatin-associated complexes such as the polycomb repressor complex and histones, though it does not directly bind DNA. In cancer, SSX4 is linked to increased cell proliferation, survival, and invasion, modulating key cell signaling pathways (MAPK/Erk, Wnt/β-catenin, Akt) that control cell cycle and epithelial-mesenchymal transition. Its immunogenicity and cancer-restricted expression profile make SSX4 an attractive candidate for immunotherapy and cancer vaccine development.

Other names

Protein SSX4SSX4ACT5.4Cancer/testis antigen 5.4Synovial sarcoma, X breakpoint 4

For targeted immunotherapies (experimental): development of cancer vaccines and T-cell therapies directed against SSX4/SSX peptides to stimulate immune response against tumor cells expressing SSX4. For epigenetic drugs: increase SSX4 expression on tumor cells, making them more visible to immune response; not direct targeting of SSX4 activity but induction of its expression.